Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evolent HealthEVH -3.64%64 EV-to-EBIT is -2.78 as of Jul. 30, 2026. GuruFocus rates EVH with a GF Score™ of 64/100 and a GF Value™ of $11.50 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 471 Healthcare Providers & Services companies, Evolent Health ranks worse than 212314.01% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Evolent Health's Enterprise Value for the quarter that ended in Mar. 2026 was $1,100 Mil.
Evolent Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-432 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolent Health EV-to-EBIT Related Terms
Evolent Health EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Evolent Health's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Evolent Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolent Health EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Evolent Health's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Evolent Health's EV-to-EBIT falls into.
Evolent Health's current Enterprise Value is $1,201 Mil.
Evolent Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-432 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolent Health (EVH) has a EV-to-EBIT of -2.78 as of Jul. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Evolent Health and its competitors. According to the industry distribution chart, Evolent Health ranks #999999 out of 471 companies in the Healthcare Providers & Services industry.
Is Evolent Health's EV-to-EBIT too high?
Evolent Health's current EV-to-EBIT is -2.78. Based on the distribution chart, Evolent Health ranks #999999 out of 471 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Evolent Health has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolent Health's EV-to-EBIT compare to NRC and SOPH?
According to the Healthcare Providers & Services industry distribution chart, Evolent Health ranks #999999 out of 471 companies for EV-to-EBIT. This places Evolent Health in the lower half of its industry. The industry median EV-to-EBIT is 15.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.73, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Evolent Health and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolent Health's current EV-to-EBIT is -2.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolent Health stock overvalued right now?
Based on GuruFocus' analysis, Evolent Health (EVH) is currently considered Possible Value Trap. The stock's GF Value™ is $11.50, compared to a current price of $3.18 — trading 72.3% below its estimated fair value. The current EV-to-EBIT is -2.78. Evolent Health's overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Evolent Health (EVH), the current EV-to-EBIT is -2.78 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evolent Health (EVH) Overvalued in 2026?
Based on GuruFocus' analysis, Evolent Health stock appears to be undervalued.
The current stock price of $3.18 is trading 72.3% below its estimated GF Value™ of $11.50.
GuruFocus considers Evolent Health to be Possible Value Trap.
Key valuation signals for EVH:
EV-to-EBIT: -2.78
GF Value™: $11.50 vs. price of $3.18 (72.3% below fair value)
No single metric tells the full story. See the EVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
64GF Score
Get the complete analysis for EVH
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVH has been successfully added to your 
